Atorvastatin attenuates murine anti-glomerular basement membrane glomerulonephritis

Kidney International

Volumn 77, Issue 5, 2010, Pages 428-435

  Eller, Philipp ^a   Eller, Kathrin ^a   Wolf, Anna M ^a   Reinstadler, Sebastian J ^a   Tagwerker, Andrea ^a   Patsch, Josef R ^a   Mayer, Gert ^a   Rosenkranz, Alexander R ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Glomerulonephritis; Immunology and pathology; Statins

Indexed keywords

ATORVASTATIN; GAMMA INTERFERON; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 6; TRANSCRIPTION FACTOR FOXP3;

ALBUMINURIA; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GLOMERULONEPHRITIS; HISTOLOGY; HUMORAL IMMUNITY; IMMUNOMODULATION; KIDNEY; LYMPH NODE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; MOUSE; NEPHRITIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; GLOMERULAR BASEMENT MEMBRANE; GLOMERULONEPHRITIS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-10; KIDNEY GLOMERULUS; MALE; MICE; MICE, INBRED C57BL; PYRROLES; T-LYMPHOCYTE SUBSETS; TH1 CELLS;

EID: 76749128896     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.478     Document Type: Article

References (48)

1. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002; 110: 285-288.
2. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006; 6: 358-370.
3. Zhang X, Jin J, Peng X et al. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol 2008; 180: 6988-6996.
4. Mausner-Fainberg K, Luboshits G, Mor A et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 2008; 197: 829-839.
5. Mira E, Leon B, Barber DF et al. Statins induce regulatory T cell recruitment via a CCL1 dependent pathway. J Immunol 2008; 181: 3524-3534.
6. Aktas O, Waiczies S, Smorodchenko A et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003; 197: 725-733.
7. Leung BP, Sattar N, Crilly A et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003; 170: 1524-1530.
8. McKay A, Leung BP, McInnes IB et al. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 2004; 172: 2903-2908.
9. Youssef S, Stuve O, Patarroyo JC et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78-84.
10. Zeiser R, Youssef S, Baker J et al. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood 2007; 110: 4588-4598.
11. Hamadani M, Awan FT, Devine SM. The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. Blood 2008; 111: 3901-3902.
12. McCarey DW, McInnes IB, Madhok R et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363: 2015-2021.
13. Fellstrom BC, Jardine AG, Schmieder R et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407.
14. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248. (Pubitemid 41058323)
15. Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024-2031.
16. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207.
17. Lawman S, Mauri C, Jury EC et al. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 2004; 173: 7641-7646.
18. Christensen M, Su AW, Snyder RW et al. Simvastatin protection against acute immune-mediated glomerulonephritis in mice. Kidney Int 2006; 69: 457-463.
19. Fujii M, Inoguchi T, Maeda Y et al. Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. Kidney Int 2007; 72: 473-480.
20. Kramer S, Kron S, Wang-Rosenke Y et al. Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis. Am J Physiol Renal Physiol 2008; 294: F801-F811.
21. Fried LF. Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. Kidney Int 2008; 74: 571-576.
22. Khwaja A, Sharpe CC, Noor M et al. The role of geranylgeranylated proteins in human mesangial cell proliferation. Kidney Int 2006; 70: 1296-1304.
23. Ooi JD, Phoon RK, Holdsworth SR et al. IL-23, not IL-12, directs autoimmunity to the Goodpasture antigen. J Am Soc Nephrol 2009; 20: 980-989.
24. Paust HJ, Turner JE, Steinmetz OM et al. The IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritis. J Am Soc Nephrol 2009; 20: 969-979.
25. Wolf D, Hochegger K, Wolf AM et al. CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J Am Soc Nephrol 2005; 16: 1360-1370. (Pubitemid 41716520)
26. Wu J, Hicks J, Borillo J et al. CD4(+) T cells specific to a glomerular basement membrane antigen mediate glomerulonephritis. J Clin Invest 2002; 109: 517-524.
27. Duffield JS, Tipping PG, Kipari T et al. Conditional ablation of macrophages halts progression of crescentic glomerulonephritis. Am J Pathol 2005; 167: 1207-1219.
28. Chakrabarti R, Engleman EG. Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation. J Biol Chem 1991; 266: 12216-12222.
29. Cuthbert JA, Lipsky PE. A product of mevalonate proximal to isoprenoids is the source of both a necessary growth factor and an inhibitor of cell proliferation. Trans Assoc Am Physicians 1991; 104: 97-106.
30. Azuma RW, Suzuki J, Ogawa M et al. HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. Cardiovasc Res 2004; 64: 412-420.
31. Phoon RK, Kitching AR, Odobasic D et al. T-bet deficiency attenuates renal injury in experimental crescentic glomerulonephritis. J Am Soc Nephrol 2008; 19: 477-485.
32. Liu W, Li WM, Gao C et al. Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. J Autoimmu 2005; 25: 258-263.
33. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/ T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13: 139-145.
34. Kagami S, Owada T, Kanari H et al. Protein geranylgeranylation regulates the balance between Th17 cells and Foxp3+ regulatory T cells. Int Immunol 2009; 21: 679-689.
35. Trinchieri G. Interleukin-10 production by effector T cells: Th1 cells show self control. J Exp Med 2007; 204: 239-243.
36. Maynard CL, Weaver CT. Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. Immunol Rev 2008; 226: 219-233.
37. Broady R, Levings MK. Graft-versus-host disease: suppression by statins. Nat Med 2008; 14: 1155-1156.
38. Fouser LA, Wright JF, Dunussi-Joannopoulos K et al. Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev 2008; 226: 87-102.
39. Weber C, Erl W, Weber KS et al. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997; 30: 1212-1217.
40. Edgtton KL, Kausman JY, Li M et al. Intrarenal antigens activate CD4+ cells via co-stimulatory signals from dendritic cells. J Am Soc Nephrol 2008; 19: 515-526.
41. Hochegger K, Jansky GL, Soleiman A et al. Differential effects of rapamycin in anti-GBM glomerulonephritis. J Am Soc Nephrol 2008; 19: 1520-1529.
42. Hochegger K, Siebenhaar F, Vielhauer V et al. Role of mast cells in experimental anti-glomerular basement membrane glomerulonephritis. Eur J Immunol 2005; 35: 3074-3082.
43. Rosenkranz AR, Mendrick DL, Cotran RS et al. P-selectin deficiency exacerbates experimental glomerulonephritis: a protective role for endothelial P-selectin in inflammation. J Clin Invest 1999; 103: 649-659.
44. Endo A, Tsujita Y, Kuroda M et al. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta 1979; 575: 266-276.
45. Kita T, Brown MS, Goldstein JL. Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J Clin Invest 1980; 66: 1094-1100.
46. Tancevski I, Frank S, Massoner P et al. Increased plasma levels of LDL cholesterol in rabbits after adenoviral overexpression of human scavenger receptor class B type I. J Mol Med 2005; 83: 927-932.
47. Kitching AR, Holdsworth SR, Ploplis VA et al. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med 1997; 185: 963-968.
48. Mayadas TN, Mendrick DL, Brady HR et al. Acute passive anti-glomerular basement membrane nephritis in P-selectin-deficient mice. Kidney Int 1996; 49: 1342-1349.